NCT05286788 - MEKTOVI® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 10, 2023

Primary Completion Date

April 10, 2027

Study Completion Date

April 10, 2027

Conditions

Adamantinous CraniopharyngiomaRecurrent Adamantinomatous Craniopharyngioma

Interventions

DRUG

Binimetinib Oral Tablet [Mektovi]

Binimetinib oral continuous dosing 32 mg/m2 PO BID for 4 weeks

Trial Locations (10)

2031

RECRUITING

Sydney Children's Hospital, Randwick

4101

RECRUITING

Queensland Children's Hospital, South Brisbane

6000

RECRUITING

Perth Children's Hospital, Perth

20010

RECRUITING

Children's National Medical Center, Washington D.C.

33155

RECRUITING

Nicklaus Children's Hospital, Miami

43205

RECRUITING

Nationwide Children's Hospital, Columbus

45229

RECRUITING

Cincinnati Children's Hospital Medical Center, Cincinnati

80045

RECRUITING

Children's Hospital Colorado, Aurora

V6H 3N

RECRUITING

British Columbia Children's Hospital, Vancouver

Unknown

RECRUITING

CHU Sainte-Justine, Montreal

All Listed Sponsors

collaborator

Children's Hospital Colorado

OTHER

lead

Nationwide Children's Hospital

OTHER